🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. Cyclophosphamide+Pemetrexed+5-Fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Thyroid Gland Carcinoma

    phase 2 small molecule active

    1 trial

  2. DCC-3014, DCC-3014, DCC-3014

    Lacuna Pharma Pty Ltd

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  3. DCVax-Direct

    NORTHWEST BIOTHERAPEUTICS INC

    Locally Advanced Tumor

    phase 2 mab active

    1 trial

  4. DEXAMETHASONE , ENFORTUMAB VEDOTIN , -, PARACETAMOL , -, MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  6. DS-3939a

    Daiichi Sankyo

    Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  7. DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  8. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  9. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  10. Darleukin, Fibromun

    Philogen S.p.A.

    locally advanced basal cell carcinoma patients

    phase 2 small molecule active

    1 trial

  11. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  12. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

  14. Debio 4228, Debio 4228

    Alphapharm Pty Ltd

    advanced prostate cancer

    phase 2 small molecule active

    1 trial

  15. Description and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  16. Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick control positivo, Diagnóstico prick control negativo, Diagnóstico prick Dermatophagoides pteronyssinus

    Advanced Accelerator Applications

    Allergies

    phase 2 small molecule active

    1 trial

  17. Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick control negativo, Diagnóstico prick control positivo

    Advanced Accelerator Applications

    Allergies

    phase 2 small molecule active

    1 trial

  18. Disitamab Vedotin

    Pfizer Australia Pty Ltd

    HER2 Expressing Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  19. Docetaxel + Sunitinib

    Samsung Bioepis NL B.V.

    Advanced Gastric Cancer

    phase 2 small molecule completed

    1 trial

  20. Domvanalimab

    Arcus Biosciences

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Doxycycline

    United Therapeutics Europe Ltd

    Advanced Malignant Neoplasm

    phase 2 small molecule completed

    1 trial

  22. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  23. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  24. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources